Cognitive disorder
diseaseOn this page
Summary
Cognitive disorder (MONDO:0002039) is a disease (an umbrella term covering 6 Mondo subtypes) with 6 GWAS associations across 9 studies and 71 clinical trials. Top therapeutic interventions include dextromethorphan, selegiline hydrochloride, and propofol. A subtype of psychiatric disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Umbrella term: 6 Mondo subtypes
- GWAS associations: 6
- Clinical trials: 71
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | cognitive disorder |
| Mondo ID | MONDO:0002039 |
| MeSH | D019965 |
| DOID | DOID:1561 |
| NCIT | C92196 |
| SNOMED CT | 443265004 |
| UMLS | C0009241 |
| MedGen | 40371 |
| Is cancer (heuristic) | no |
Also known as: cognitive disorder
Data availability: 6 GWAS associations (9 studies).
Disease family
This is a subtype of psychiatric disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › cognitive disorder
Related subtypes (13): sexual disorder, dissociative disorder, impulse control disorder, personality disorder, factitious disorder, substance-related disorder, somatoform disorder, mental disorder, eating disorder, enuresis, Alice in Wonderland syndrome, catatonia, body integrity dysphoria
Subtypes (6): amnestic disorder, dementia, alexia, psychotic disorder, delirium, subjective cognitive decline
Genetics & variants
GWAS landscape
6 GWAS associations across 9 studies. Top hits map to 1 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs429358 | 5e-306 | APOE | T | 0.41 |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90476493 | Verma A | 2024 | 33,956 | 397,556 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90476492 | Verma A | 2024 | 8,216 | 108,456 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90480737 | Verma A | 2024 | 8,216 | 108,456 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90651174 | Liu TY | 2025 | 7,262 | 225,176 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
| GCST90476491 | Verma A | 2024 | 3,319 | 54,404 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90435835 | Zhou W | 2018 | 1,970 | 402,383 | Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. |
| GCST90481675 | Verma A | 2024 | 202 | 6,530 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90043695 | Jiang L | 2021 | 195 | 456,153 | A generalized linear mixed model association tool for biobank-scale data. |
| GCST90837528 | Koyama S | 2025 | 0 | 0 | Genetics and context for precision health in Greater Boston. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 1 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 0 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 1 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 0 |
Functional consequences
| Consequence | Count |
|---|---|
| missense_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs429358 | 19 | 44908684 | T>C | 0.14 | missense_variant | APOE | 5e-306 | Tier 1: coding |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 71.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 52 |
| PHASE1 | 9 |
| PHASE2 | 6 |
| PHASE4 | 3 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01184638 | PHASE4 | UNKNOWN | Long-term Outcome of General Anesthesia on Dysgnosia |
| NCT01881646 | PHASE4 | COMPLETED | Postoperative Neuroinflammation and Cognitive Dysfunction After Abdominal Surgery |
| NCT02782429 | PHASE4 | UNKNOWN | The Role of Ketamine in Preventing Cognitive Dysfunctions in Postoperative Period of Cardiac Surgery |
| NCT04295681 | PHASE3 | COMPLETED | Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders |
| NCT07279714 | PHASE2 | RECRUITING | Fisetin in Mild Alzheimer’s Disease |
| NCT00002154 | PHASE2 | COMPLETED | A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia |
| NCT01635348 | PHASE2 | COMPLETED | Thinking, Walking Outcomes by Type of Exercise |
| NCT02324153 | PHASE2 | COMPLETED | Ramelteon in the Prevention of Post-operative Delirium |
| NCT02554253 | PHASE2 | COMPLETED | The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction |
| NCT03538522 | PHASE2 | COMPLETED | A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831 |
| NCT00002148 | PHASE1 | COMPLETED | Parallel Group, Placebo-Controlled, Tolerability, Safety, and Efficacy Study of OPC-14117 in HIV Dementia |
| NCT00743405 | PHASE1 | COMPLETED | Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects |
| NCT00937846 | PHASE1 | COMPLETED | Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study |
| NCT00950586 | PHASE1 | COMPLETED | Safety, Blood Levels, Drug Interaction and Effects of Repeated Doses of GSK1034702 |
| NCT02342041 | PHASE1 | COMPLETED | A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects |
| NCT02575482 | PHASE1 | COMPLETED | A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects |
| NCT02881294 | PHASE1 | COMPLETED | A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-G3031 in Healthy Subjects |
| NCT03031574 | PHASE1 | COMPLETED | A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-D4010 in Healthy Subjects |
| NCT05486195 | PHASE1 | COMPLETED | A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food Effect |
| NCT04754906 | Not specified | RECRUITING | Analysis of Motor Skills in Subjects Aged 55 and Over: the Role of Cognitive Abilities for Planning Movement. |
| NCT05600946 | Not specified | RECRUITING | Characterization of Dysmorphology in Subjects With Creatine Transporter Deficiency |
| NCT05888961 | Not specified | RECRUITING | Single-center Prospective Longitudinal Study of Taste in Patients With Cognitive Disorders at Different Stages of Severity (Isolated Cognitive Complaint, Minor or Major Neurocognitive Alzheimer-type Disorders) by Analysis of Gustatory Evoked Potentials |
| NCT06088953 | Not specified | RECRUITING | EARLY DETECTION OF DEAFNESS IN A MEMORY CENTER |
| NCT06546813 | Not specified | RECRUITING | Outcomes of ICT Assistive Technology in RehabiliTAtIoN Pathways |
| NCT06597591 | Not specified | RECRUITING | Virtual Reality Training for Inhibitory Control in Neurocognitive Disorders |
| NCT06697418 | Not specified | ENROLLING_BY_INVITATION | The Effect of Physical Activity Level Evaluated by Wrist-wearable Devices on Cardiovascular Disease Risk and Other Outcomes in Peritoneal Dialysis Patients |
| NCT06801171 | Not specified | RECRUITING | A Mixed Intervention to Improve Resilience for Patient With Neurocognitive Disorders |
| NCT06871384 | Not specified | RECRUITING | Dietary Strategy to Tackle Cognitive and Locomotor Abilities in Early Elderly Subjects |
| NCT06895109 | Not specified | ACTIVE_NOT_RECRUITING | Cognitive Functions in Severe Acquired Brain Injury After Cranioplasty |
| NCT06964581 | Not specified | RECRUITING | Cognitive Rehabilitation of Deficits in Patients With Multiple Sclerosis |
| NCT06995443 | Not specified | RECRUITING | Breast Cancer and Chemobrain : Effects of Photobiomodulation on the Improvement of Perceived Cognitive Impairment |
| NCT07182396 | Not specified | RECRUITING | Effects of Video Games and Ball Tossing on Eye Hand Coordination in Elderly With Mild Cognitive Impairment. |
| NCT07213362 | Not specified | NOT_YET_RECRUITING | Study on the Effect of Online Cognitive Training Doses on Cognitive Function in Individuals With Mild Cognitive Decline |
| NCT07242495 | Not specified | RECRUITING | Additional Effects of Immersive vr 360 Degree Videos With Aerobic Exercises on Cognitive Functions in Elderly With Mild Cognitive Impairment |
| NCT07388160 | Not specified | NOT_YET_RECRUITING | Neuroinflammatory Biomarkers After General Anesthesia: A Comparison Study |
| NCT00001103 | Not specified | COMPLETED | HIV Levels in Cerebrospinal Fluid and Brain Function in Patients Receiving Anti-HIV Drugs |
| NCT00027040 | Not specified | COMPLETED | A Study of Decreased Mental Function Associated With HIV |
| NCT00458094 | Not specified | COMPLETED | Peer Support for Increasing Physical Activity in People With Serious Mental Illnesses |
| NCT01339195 | Not specified | COMPLETED | Post-stroke Cognitive Impairment and Dementia |
| NCT01481246 | Not specified | UNKNOWN | Neurocognitive Study for the Aging-a Longitudinal Study With a Greek Cypriot Cohort |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DEXTROMETHORPHAN | 4 | 3 |
| SELEGILINE HYDROCHLORIDE | 4 | 2 |
| PROPOFOL | 4 | 1 |
| RAMELTEON | 4 | 1 |
| RIBOFLAVIN | 4 | 1 |
| SEVOFLURANE | 4 | 1 |
| LIPOIC ACID, ALPHA | 3 | 1 |
| MICROCRYSTALLINE CELLULOSE | 3 | 1 |
| SUVN-G3031 | 2 | 2 |
| FISETIN | 2 | 1 |
| PLOSARACETAM | 2 | 1 |
| GSK-1034702 | 1 | 2 |
| SUVN-D4010 | 1 | 2 |
| CHEMBL1314409 | 0 | 2 |
| CHEMBL1234071 | 0 | 1 |
| CHEMBL511565 | 0 | 1 |
| CHEMBL5267279 | 0 | 1 |
| THIOCTIC ACID | 0 | 1 |